Additional therapy for cholesterol lowering in ezetimibe-treated, statin-intolerant patients in clinical practice: results from an internal audit of a university lipid clinic

References

• Cholesterol Treatment Trialists’ (CTT) Collaboration; Fulcher J, O’Connell R, Voysey M, et al. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet 2015;385:1397-405
   PubMed Web of Science ®Google Scholar
• Lv HL, Jin DM, Liu M, et al. Long-term efficacy and safety of statin treatment beyond six years: a meta-analysis of randomized controlled trials with extended follow-up. Pharmacol Res 2014;81:64-73
   PubMed Web of Science ®Google Scholar
• Rosenbaum D, Dallongeville J, Sabouret P, Bruckert E. Discontinuation of statin therapy due to muscular side effects: a survey in real life. Nutr Metab Cardiovasc Dis 2013;23:871-5
   PubMed Web of Science ®Google Scholar
• Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. Clin Ther 2008;30:2167-79
   PubMed Web of Science ®Google Scholar
• Alfirevic A, Neely D, Armitage J, et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 2014;96:470-6
   PubMed Web of Science ®Google Scholar
• Graham DJ, Staffa JA, Shatin D, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004;292:2585-90
   PubMed Web of Science ®Google Scholar
• Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update. Can J Cardiol 2013;29:1553-68
   Web of Science ®Google Scholar
• Jacobson TA. NLA Task Force on Statin Safety – 2014 update. J Clin Lipidol 2014;8(Suppl 3):S1-S4
   Google Scholar
• Ahmad Z. Statin intolerance. Am J Cardiol 2014;113:1765-71
   PubMed Web of Science ®Google Scholar
• Riphagen IJ, van der Veer E, Muskiet FA, DeJongste MJ. Myopathy during statin therapy in the daily practice of an outpatient cardiology clinic: prevalence, predictors and relation with vitamin D. Curr Med Res Opin 2012;28:1247-52
   PubMed Web of Science ®Google Scholar
• Stroes ES, Thompson PD, Corsini A, et al.; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance – an attempt at a unified definition. Position paper from an International Lipid Expert Panel. Arch Med Sci 2015;11:1-23
   PubMed Web of Science ®Google Scholar
• Naci H, Brugts J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. Circ Cardiovasc Qual Outcomes 2013;6:390-9
   PubMed Web of Science ®Google Scholar
• Navarese EP, Buffon A, Andreotti F, et al. Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. Am J Cardiol 2013;111:1123-30
   PubMed Web of Science ®Google Scholar
• Sattar NA, Ginsberg H, Ray K, et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. Atheroscler Suppl 2014;15:1-15
   PubMed Web of Science ®Google Scholar
• Joosten H, Visser ST, van Eersel ME, et al. Statin use and cognitive function: population-based observational study with long-term follow-up. PLoS One 2014;9:e115755
   PubMed Web of Science ®Google Scholar
• Richardson K, Schoen M, French B, et al. Statins and cognitive function: a systematic review. Ann Intern Med 2013;159:688-97
   PubMed Web of Science ®Google Scholar
• Rojas-Fernandez CH, Cameron JC. Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann Pharmacother 2012;46:549-57
   PubMed Web of Science ®Google Scholar
• Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the Cleveland Clinic experience. Am Heart J 2013;166:597-603
   PubMed Web of Science ®Google Scholar
• Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. Ann Pharmacother 2013;47:398-404
   PubMed Web of Science ®Google Scholar
• Bays HE, Moore PB, Drehobl MA, et al.; Ezetimibe Study Group. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 2001;23:1209-30
   PubMed Web of Science ®Google Scholar
• Gagné C, Bays HE, Weiss SR, et al.; Ezetimibe Study Group. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90:1084-91
   PubMed Web of Science ®Google Scholar
• Cicero AF, Ferroni A, Ertek S. Tolerability and safety of commonly used dietary supplements and nutraceuticals with lipid-lowering effects. Expert Opin Drug Saf 2012;11:753-66
   PubMed Web of Science ®Google Scholar
• European Association for Cardiovascular Prevention & Rehabilitation; Reiner Z, Catapano AL, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
   Google Scholar
• Kennedy SP, Barnas GP, Schmidt MJ, et al. Efficacy and tolerability of once-weekly rosuvastatin in patients with previous statin intolerance. J Clin Lipidol 2011;5:308-15
   PubMed Web of Science ®Google Scholar
• Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008;101:483-5
   PubMed Web of Science ®Google Scholar
• Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: an observational study. Curr Med Res Opin 2012;28:371-8
   PubMed Web of Science ®Google Scholar
• Nakamura H, Arakawa K, Itakura H, et al.; MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006;368:1155-63
   PubMed Web of Science ®Google Scholar
• Lu Z, Kou W, Du B, et al.; Chinese Coronary Secondary Prevention Study Group. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. Am J Cardiol 2008;101:1689-93
   PubMed Web of Science ®Google Scholar
• Gerards MC, Terlou RJ, Yu H, Koks CH, Gerdes VE. Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis. Atherosclerosis 2015;240:415-23
   PubMed Web of Science ®Google Scholar
• Gordon RY, Cooperman T, Obermeyer W, Becker DJ. Marked variability of monacolin levels in commercial red yeast rice products: buyer beware! Arch Intern Med 2010;170:1722-7
   PubMed Web of Science ®Google Scholar
• Marazzi G, Caciotti L, Pelliccia F, et al. Long-term effects of nutraceuticals (berberine, red yeast rice, policosanol) in elderly hypercholesterolemic patients. Adv Ther 2011;28:1105-13
   PubMed Web of Science ®Google Scholar
• Cicero AF, Derosa G, Borghi C. Red yeast rice and statin-intolerant patients. Am J Cardiol 2010;105:1504
   PubMed Web of Science ®Google Scholar
• Kumar SS, Lahey KA, Day A, LaHaye SA. Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia. Lipids Health Dis 2009;8:56
   PubMed Web of Science ®Google Scholar
• Lan J, Zhao Y, Dong F, et al. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. J Ethnopharmacol 2015;161:69-81
   PubMed Web of Science ®Google Scholar
• Derosa G, Maffioli P, Cicero AF. Berberine on metabolic and cardiovascular risk factors: an analysis from preclinical evidences to clinical trials. Expert Opin Biol Ther 2012;12:1113-24
   PubMed Web of Science ®Google Scholar
• Brensike JF, Levy RI, Kelsey SF, et al. Effects of therapy with cholestyramine on progression of coronary arteriosclerosis: results of the NHLBI Type II Coronary Intervention Study. Circulation 1984;69:313-24
   PubMed Web of Science ®Google Scholar
• Abourbih S, Filion KB, Joseph L, et al. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Am J Med 2009;122:962.e1-8
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97
   PubMed Web of Science ®Google Scholar
• Robinson JG, Farnier M, Krempf M, et al.; ODYSSEY Long Term Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1489-99
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Wiviott SD, et al.; Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372:1500-9
   PubMed Web of Science ®Google Scholar
• De Vera MA, Bhole V, Burns LC, Lacaille D. Impact of statin adherence on cardiovascular disease and mortality outcomes: a systematic review. Br J Clin Pharmacol 2014;78:684-98
   PubMed Web of Science ®Google Scholar
• Slejko JF, Ho M, Anderson HD, et al. Adherence to statins in primary prevention: yearly adherence changes and outcomes. J Manag Care Pharm 2014;20:51-7
   PubMed Web of Science ®Google Scholar
• Banach M, Serban C, Sahebkar A, et al.; Lipid and Blood Pressure Meta-analysis Collaboration Group. Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials. Mayo Clin Proc 2015;90:24-34
   PubMed Web of Science ®Google Scholar
• Taylor BA, Lorson L, White CM, Thompson PD. A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy. Atherosclerosis 2015;238:329-35
   PubMed Web of Science ®Google Scholar
• Cho HT, Salvia-Trujillo L, Kim J, et al. Droplet size and composition of nutraceutical nanoemulsions influences bioavailability of long chain fatty acids and Coenzyme Q10. Food Chem 2014;156:117-22
   PubMed Web of Science ®Google Scholar